Phase I Study With Dose Expansion of Acalabrutinib and Durvalumab (MEDI 4736) in Primary and Secondary Central Nervous System Lymphoma
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Acalabrutinib (Primary) ; Durvalumab (Primary)
- Indications CNS cancer; Diffuse large B cell lymphoma; Lymphoma
- Focus Adverse reactions
- 10 Jul 2024 Planned End Date changed from 31 Oct 2030 to 31 Dec 2027.
- 10 Jul 2024 Planned primary completion date changed from 25 Jul 2025 to 31 Mar 2026.
- 20 Sep 2023 Planned End Date changed from 31 Aug 2028 to 31 Oct 2030.